Alan Heldman

From Wikipedia, the free encyclopedia

Alan W. Heldman, M.D. (born 1962) is an American interventional cardiologist.

Heldman graduated from Harvard College, University of Alabama School of Medicine, and completed residency and fellowship training at Johns Hopkins University School of Medicine. He held positions on the faculty of Johns Hopkins from 1995 to 2007. In 2007 he became Clinical Chief of Cardiology at the University of Miami, Leonard M. Miller School of Medicine.

He published one of the first studies showing that a drug-coated stent (now known as a drug-eluting stent) could prevent restenosis[1]. His research interests include delivery of stem cells[2] to the heart for repair of myocardial infarction[3].

His clinical interests include high risk and complex coronary intervention, and treatment of hypertrophic cardiomyopathy, including with alcohol septal ablation[4].

[edit] References

  1. ^ Heldman A, Cheng L, Jenkins G, Heller P, Kim D, Ware M, Nater C, Hruban R, Rezai B, Abella B, Bunge K, Kinsella J, Sollott S, Lakatta E, Brinker J, Hunter W, Froehlich J (2001). "Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis.". Circulation 2001 May 8;103(18):2289-95. PMID 11342479
  2. ^ Heldman AW, Hare JM. Cell therapy for myocardial infarction: Special delivery. J Mol Cell Cardiol. 2007 Dec 4. PMID 18234211]
  3. ^ Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, Cattaneo S, Durand DJ, Fitton T, Kuang JQ, Stewart G, Lehrke S, Baumgartner WW, Martin BJ, Heldman AW, Hare JM. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11474-9. PMID 16061805
  4. ^ Heldman AW, Wu KC, Abraham TP, Cameron DE. Myectomy or alcohol septal ablation: surgery and percutaneous intervention go another round. J Am Coll Cardiol. 2007 Jan 23;49(3):358-60. PMID: 17239718

[edit] External links